This paper is in the following e-collection/theme issue:

Clinical Information and Decision Making (1642) mHealth in a Clinical Setting (676) Decision Support for Health Professionals (1336) Dementia and Cognitive Decline (586) Digital Health Reviews (1513) New Methods (1029) Research Instruments, Questionnaires, and Tools (661)

Published on in Vol 27 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/68454, first published .
Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Authors of this article:

Danko Jeremic1 Author Orcid Image ;   Juan D Navarro-Lopez1 Author Orcid Image ;   Lydia Jimenez-Diaz1 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Xing H, Yue S, Qin R, Du X, Wu Y, Zhangsun D, Luo S. Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review. International Journal of Molecular Sciences 2025;26(8):3905 View